

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions and listings of claims in the application. Please amend the claims as indicated below without prejudice.

Claims 1-23 (canceled)

Claim 24 (Previously Presented): A method of removing amyloid deposits in a patient comprising administering to the patient an antibody or immunoglobulin polypeptide or fragment thereof in an amount effective to remove amyloid deposits, wherein the antibody or immunoglobulin polypeptide or fragment thereof opsonizes an amyloid fibril and induces removal of amyloid deposits.

Claims 25-27 (canceled)

Claim 28 (Withdrawn): The method of claim 24, wherein the antibody or immunoglobulin polypeptide or fragment thereof is raised against an immunoglobulin light-chain.

Claim 29 (canceled).

Claim 30 (Previously Presented): The method of claim 24, wherein the antibody or immunoglobulin polypeptide or fragment thereof is a monoclonal antibody.

Claim 31 (Previously Presented): The method of claim 30, wherein the monoclonal antibody is a completely human antibody.

Claim 32 (Previously Presented): The method of claim 30, wherein the monoclonal antibody is a humanized antibody.

Claim 33 (Previously Presented): The method of claim 30, wherein the monoclonal antibody is a chimeric antibody.

Claim 34 (Previously Presented): The method of claim 33, wherein the chimeric antibody is a humanized antibody.

Claim 35 (Previously Presented): The method of claim 30, wherein the monoclonal antibody is a labeled antibody.

Claim 36 (Withdrawn): The method of claim 30, wherein the monoclonal antibody is selected from the group consisting of 88 (31-8C7) (ATCC accession number PTA-103), 61(57-18H12) (ATCC accession number PTA-104), 64 (11-1F4) (ATCC accession number PTA-105), and combinations thereof.

Claim 37 (Previously Presented): The method of claim 24, wherein the antibody or immunoglobulin fragment is a Fv fragment, Fab fragment, F(ab'') fragment, F(ab')<sub>2</sub> fragment, or SvFv fragment.

Claim 38 (Previously Presented): The method of claim 24, wherein the antibody or immunoglobulin is a single chain antibody.

Claim 39 (Previously Presented): The method of claim 24, wherein the antibody or immunoglobulin has cross-isotype reactivity.

Claim 40 (Previously Presented): The method of claim 24, wherein the antibody or immunoglobulin is reactive with a non-light chain amyloid.

Claim 41 (Previously Presented): The method of claim 40, wherein the antibody or immunoglobulin is reactive with Alzheimer's protein A $\beta$ .

Claim 42 (Previously Presented): The method of claim 24, wherein the patient is a human.

Claim 43 (Previously Presented): The method of claim 24, wherein the antibody or immunoglobulin polypeptide or fragment thereof is reactive with an amyloid fibril other than the amyloid fibril or component or precursor thereof, against which the immunoglobulin polypeptide or fragment thereof was raised.

Claim 44 (Previously Presented): The method of claim 24, wherein more than one antibody or immunoglobulin polypeptide or fragment thereof is administered to the patient.

Claim 45 (Previously Presented): The method of claim 24, wherein the antibody or immunoglobulin polypeptide or fragment thereof is administered with a carrier.

Claim 46 (Previously Presented): A method of removing amyloid deposits in a patient comprising administering to the patient an antibody or immunoglobulin polypeptide or fragment thereof in an amount effective to remove amyloid deposits, wherein the antibody or immunoglobulin polypeptide or fragment thereof opsonizes a non-light chain amyloid fibril and induces removal of amyloid deposits.

Claim 47 (Previously Presented): A method of claim 46, wherein the antibody or immunoglobulin polypeptide or fragment thereof is humanized.

Claim 48 (Previously Presented): A method of claim 46, wherein the antibody or immunoglobulin polypeptide or fragment thereof is human.

Claim 49 (Previously Presented): A method of claim 46, wherein the antibody or immunoglobulin polypeptide is a monoclonal antibody raised against an amyloid fibril.

Claim 50 (Previously Presented): The method of claim 24, wherein maintenance doses are administered to the patient after removal of said amyloid deposits.